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Activation of the hypothalamo-pituitary–adrenal (HPA) axis is a basic reaction of animals to
environmental perturbations that threaten homeostasis. These responses are ultimately
regulated by neurons residing within the paraventricular nucleus (PVN) of the hypothal-
amus. Within the PVN, corticotrophin-releasing hormone (CRH), vasopressin (AVP), and
oxytocin (OT) expressing neurons are critical as they can regulate both neuroendocrine
and autonomic responses. Estradiol (E2) and testosterone (T) are well known reproductive
hormones; however, they have also been shown to modulate stress reactivity. In rodent
models, evidence shows that under some conditions E2 enhances stress activated adreno-
corticotropic hormone (ACTH) and corticosterone secretion. In contrast, T decreases the
gain of the HPA axis. The modulatory role of testosterone was originally thought to be via
5 alpha reduction to the potent androgen dihydrotestosterone (DHT) and its subsequent
binding to the androgen receptor, whereas E2 effects were thought to be mediated by
estrogen receptors alpha (ERalpha) and beta (ERbeta). However, DHT has been shown to
be metabolized to the ERbeta agonist, 5α- androstane 3β, 17β Diol (3β-Diol). The actions
of 3β-Diol on the HPA axis are mediated by ERbeta which inhibits the PVN response to
stressors. In gonadectomized rats, ERbeta agonists reduce CORT and ACTH responses to
restraint stress, an effect that is also present in wild-type but not ERbeta-knockout mice.
The neurobiological mechanisms underlying the ability of ERbeta to alter HPA reactivity are
not currently known. CRH, AVP, and OT have all been shown to be regulated by estradiol
and recent studies indicate an important role of ERbeta in these regulatory processes.
Moreover, activation of the CRH and AVP promoters has been shown to occur by 3β-Diol
binding to ERbeta and this is thought to occur through alternate pathways of gene regula-
tion. Based on available data, a novel and important role of 3β-Diol in the regulation of the
HPA axis is suggested.
Keywords: corticotropin releasing hormone, vasopressin, oxytocin, estrogen receptor beta, stress, androgen,
paraventricular nucleus, 3β-Diol
INTRODUCTION
The hypothalamo-pituitary–adrenal (HPA) axis represents a com-
plex series of neural signals that ultimately controls the hormonal
response to stressors. Stress, as originally deﬁned by Hans Selye
(1936) is “. . .the non-speciﬁc response of the body to any demand
for change. . ..” Thus, the HPA axis represents one of several
“non-speciﬁc” response systems that are used by the brain to
adjust multiple physiological functions in an attempt to maintain
homeostasis. Other “non-speciﬁc” responses activated by stres-
sors may include the immune system and autonomic nervous
system. Although stress may have positive (eustress) or negative
(distress) connotations, the consequences of unresolved persistent
stress responses can lead to severe neuropsychiatric disorders in
susceptible individuals (Selye, 1975).
Regulation of the HPA axis by gonadal steroid hormones is an
important consideration in anxiety and affective disorders. For
example, major depressive disorder (MDD), and anxiety disor-
ders, are current major public health concerns and are responsible
for substantial social and economic burden in developed coun-
tries (Murray and Lopez, 1997; Ustun et al., 2004). Of interest,
women are up to 2.5 times more likely than men to be diag-
nosedwithMDD in their lifetime (Fava andKendler, 2000;Kessler,
2003), and women have a signiﬁcantly higher heritability of MDD
than men (Kendler, 1998; Hettema et al., 2001). Clinical studies of
depressed patients reveal that the sex differences in incidence arise
at adolescence andmore closely coincide with androgen and estro-
gen levels rather than physical changes associated with puberty
(Warren and Brooks-Gunn, 1989; Angold and Worthman, 1993;
Angold et al., 1999). As a result, changing patterns of hormones
and hormone sensitivitymay be implicated as potential etiological
factors. In this review, we explore the steroid hormone inﬂu-
ences on the regulation of HPA axis function that could inﬂuence
www.frontiersin.org November 2011 | Volume 2 | Article 65 | 1
Handa et al. 3β-Diol and the stress response
susceptibility to disease states such as affective disorders, with
particular emphasis on androgens and estrogenic metabolites of
androgen.
THE HYPOTHALAMO-PITUITARY–ADRENAL AXIS
Glucocorticoid hormones, the end-product of the HPA axis, are
secreted by the adrenal cortex into the general circulation, under
tight hypothalamic control. The HPA axis represents a cascade
of neural and humoral signals organized by a central circadian
pacemaker and activated in response to environmental triggers.
Under non-stressed conditions, the release of corticosterone from
the rodent adrenal cortex is linked to a circadian regulatory sys-
tem (Chung et al., 2011). Circulating adrenal glucocorticoid levels
are lowest during the inactive phase (light period in rodents, dark
period in humans) and begin to rise several hours preceding the
onset of activity or awakening (L:D transition in rodents) to peak
shortly after activity onset. Thus, the rise in adrenal glucocorticoid
secretion predicts and readies physiological systems for the onset
of activity and feeding (Nader et al., 2010). The diurnal rise in glu-
cocorticoids is allowed to occur by decreases in vasopressin (AVP)
from the SCN that normally inhibit neurons in the paraventric-
ular nucleus (PVN; Szafarczyk et al., 1983; Kalsbeek et al., 1996;
Caldwell et al., 2008). Moreover, adrenal sensitivity to adrenocor-
ticotropic hormone (ACTH) changes over the day thereby altering
the corticosterone response to ACTH in a diurnal fashion (Oster
et al., 2006).
In addition to diurnal signals regulating adrenal glucocorticoid
secretion, changing environmental conditions or perceived threats
to homeostasis activate the HPA through a common ﬁnal pathway
involving neurons located in the medial parvocellular division of
the PVN of the hypothalamus. These neurons integrate excitatory
and inhibitory inputs received from multiple brain areas (Culli-
nan et al., 1996; Herman et al., 1996; Choi et al., 2007). Thus, the
motor neurons driving the HPA response to stress are neuroen-
docrine neurons that contain corticotrophin-releasing hormone
(CRH) and that project to the median eminence. The release of
CRH into the hypothalamo-hypophyseal portal system stimulates
the release of ACTH from the anterior pituitary gland by act-
ing upon the CRH-R1 receptor on corticotrophs (Aguilera et al.,
2004).
Several additional neuropeptide phenotypes make up the PVN
neurons that control HPA axis activity. Vasopressin and oxytocin
are found at high levels in magnocellular and parvocellular neu-
rons of the PVN. Although typically thought to regulate osmotic
balance and parturition, vasopressin, and oxytocin have been
shown to co-localize with CRH in discrete PVN populations and
to be co-released with CRH (Whitnall, 1988; Bondy et al., 1989;
Raadsheer et al., 1993). Vasopressin reportedly acts synergisti-
cally with CRH to potentiate CRH’s secretogogue activity at the
level of the corticotroph (Rivier and Vale, 1983; Schlosser et al.,
1994; Papadimitriou and Priftis, 2009), whereas a role for the
oxytocin in CRH neurons has not been determined (Palkovits,
2000). Nonetheless, both vasopressin and oxytocin can stimulate
ACTH secretion even in the absence of CRH (Gillies et al., 1982).
In contrast, when applied to the PVN, or injected into the third
ventricle, oxytocin inhibits HPA responses (Windle et al., 1997;
Neumann et al., 2000) suggesting the possibility that oxytocin can
be released locally from PVN neurons, perhaps through dendritic
release (Landgraf and Neumann, 2004; Neumann, 2007).
Following the release from corticotrophs of the anterior pitu-
itary, ACTH acts on the adrenal cortex to stimulate the synthesis
and secretion of CORT. Circulating CORT has numerous effects
throughout the body, one of which is to signal to the anterior
pituitary, hypothalamus, and higher brain areas to limit fur-
ther hormone secretion (Gomez et al., 1998) thus closing this
neuroendocrine negative feedback loop.
ROLES FOR GONADAL STEROIDS IN REGULATING THE HPA
AXIS
ANDROGENS AND ANDROGEN RECEPTORS
Although testosterone and estradiol are classic reproductive hor-
mones, both have been reported to regulate the HPA axis (Gaskin
and Kitay, 1970, 1971; Coyne and Kitay, 1971). Gonadectomy of
male rats increases corticosterone and ACTH responses to stress
and correspondingly, c-fos mRNA expression in the PVN is ele-
vated (Handa et al., 1994a; Viau et al., 2003; Lund et al., 2004a,b).
The effects of testosterone (T) are not through aromatization to
estradiol given that hormone replacement of castrated ratswith the
non-aromatizable androgen, dihydrotestosterone (DHT) returns
stress-responsive plasma CORT, and ACTH levels back to that
of the intact male. Hormone replacement also inhibits the stress-
induction of c-fosmRNA in the PVN (Viau, 2002;Viau et al., 2003;
Lund et al., 2004b, 2006). Additional evidence for an androgenic
regulation of HPA axis reactivity comes from studies examining
the hormonal stress response of male rats before and after puberty.
Prior to puberty,whenT levels are low, theCORT response to acute
and chronic stress is high relative to the response seen after puberty
(Viau et al., 2005; Romeo and McEwen, 2006; Follib et al., 2011).
This correlates with the increases in T that occur during the puber-
tal transition of males. However, given that Romeo et al. (2004)
have shown that T administration cannot shift the pattern of HPA
regulation in pre-pubertalmales to that of post-pubertalmales, the
involvement of T is not sufﬁcient for the pre- and post-pubertal
changes observed in HPA axis activity.
Androgens have been reported to inhibit HPA axis function
(Handa et al., 1994a) and alter CRH-immunoreactivity (ir; Binga-
man et al., 1994a) and vasopressin mRNA within the PVN (Viau
et al., 2001). Nonetheless, androgen receptors (AR) are not local-
ized in hypophysiotrophic CRH or AVP neurons within the PVN
(Bingaman et al., 1994b) and have only been reported in the dor-
sal and the ventral medial parvocellular parts of the PVN, which
are non-neuroendocrine neurons that project to spinal cord and
brainstem pre-autonomic nuclei (Bingham et al., 2006). Conse-
quently, it has been hypothesized that androgens regulate PVN
neuropeptide expression and secretion trans-synaptically. Data
supporting this hypothesis come from studies showing that AR
are in neurons projecting to the PVN (Williamson andViau, 2007)
and that the implantation of testosterone into the medial preoptic
nucleus (MPN) and bed nucleus of the stria terminalis (BnST),
brain regions that provide afferent input to the PVN, can reduce
the CORT response to acute stress (Viau and Meaney, 1996).
Testosterone micro-implants to the MPN of gonadectomized rats
can also decrease stress-induced expression of c-Fos in the PVN
and lateral septum, an effect that is blocked by lesions of the MPN
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(Williamson et al., 2010). Further, retrograde tracing studies show
that AR-ir can be found in neurons of the BnST, but not the sep-
tum, that project to the PVN (Suzuki et al., 2001). However, the
MPN/BnST are likely not the only brain site(s) mediating andro-
gen’s inhibitory effect on HPA reactivity given that stereotaxic
application of DHT to a region just above the PVN (to prevent
mechanical disruption of the PVN) is also effective in reducing
CORT andACTH responses to stress (Lund et al., 2006).We inter-
pret such data as indicating that DHT can also have direct actions
on PVN hypophysiotrophic neuron functions. However, based on
AR distribution in brain, the local inhibitory action of DHT on
PVN neurons likely occurs through a multisynaptic pathway that
involves activation/inhibition of several neural pathways and the
resulting feedback loops to inhibit activity of neurosecretory PVN
neurons. An alternate, but notmutually exclusive possibility is that
DHT may act through another receptor type found in the PVN
or in neurons projecting to the PVN. Our recent results implicate
ER beta (Lund et al., 2006), as an important receptor for DHT’s
actions.
ESTROGENS AND ESTROGEN RECEPTORS
The role of estrogens in regulating stress reactivity remains con-
troversial. Initial studies showing sex differences in corticosterone
responses to a stressor (Gaskin and Kitay, 1970) demonstrated
that sex steroid hormones could interact with the regulatory ele-
ments of the HPA axis. Gonadectomy of both males and females
reduces the sex difference and hormone replacement to gonadec-
tomized animals can reinstate the sex difference (Handa et al.,
1994b). Initial studies indicated that estradiol treatment enhanced,
and testosterone treatment inhibited HPA reactivity (Kitay, 1963;
Viau and Meaney, 1991, 1996; Burgess and Handa, 1992; Handa
et al., 1994a). For estradiol, the direction of effect has not always
been consistent, as enhancement (Isgor et al., 2003) and inhibition
(Orchedalski et al., 2007) of HPA activity following estradiol have
also been reported. Moreover, evidence is present in the literature
showing that estradiol and testosterone can act at the adrenal gland
(Kitay, 1965), anterior pituitary (Coyne and Kitay, 1971; Viau and
Meaney, 2004), and hypothalamus (Handa et al., 1994a; Viau and
Meaney, 1996; Viau et al., 2003). Thus, contributions to each level
of the axis may mediate the gonadal steroid effects on HPA func-
tion. Furthermore, amplitude and duration of hormone exposure
could also inﬂuence the actions of gonadal steroid hormone effects
on HPA axis function (Orchedalski et al., 2007).
Following the initial discovery of a second form of estrogen
receptor, termed ERbeta (Kuiper et al., 1996), its mRNA and
immunoreactivity were shown to be highly expressed by PVNneu-
rons (Shughrue et al., 1997; Laﬂamme et al., 1998; Shughrue and
Merchenthaler, 2001; Suzuki and Handa, 2004). A large number
of ERbeta-ir cells in PVN are OT positive, and ERbeta is also
found in AVP and prolactin expressing neurons (Alves et al., 1998;
Hrabovsky et al., 1998; Somponpun and Sladek, 2003; Suzuki and
Handa, 2005). Many fewer CRH neurons of the PVN express
ERbeta (Laﬂamme et al., 1998; Suzuki and Handa, 2005; Miller
et al., 2004). These data suggest that by binding to ERbeta, E2
might directly alter the function of PVN neuropeptide neurons.
Indeed, the administration of ERbeta agonists to rats cause an
inhibition of stress-induced corticosterone secretion (Lund et al.,
2006; Weiser et al., 2009), coupled with increased anxiolytic-like
behaviors (Walf et al., 2004; Lund et al., 2005; Weiser et al., 2009).
A PVN site of action in the regulation of HPA reactivity has been
demonstrated by the studies of Lund et al. (2006) who placed
ERbeta agonists in an area adjacent to the PVN and demonstrated
a reduction of stress-responsive corticosterone and ACTH secre-
tion in ovariectomized female rats. In contrast, ERalpha agonists
had an enhancing effect on corticosterone and ACTH. Little ERal-
pha is found in the PVN and it does not associate with CRH, AVP,
or OXY neurons (Simerly et al., 1990; Estacio et al., 1996; Suzuki
and Handa, 2005). Thus, a direct action of E2 that is mediated
by ERalpha acting through neuropeptide neurons of the PVN to
regulate stress reactivity appears unlikely.
SYNTHESIS AND METABOLISM OF GONADAL STEROID
HORMONES
In all steroid-synthesizing tissues, the conversion of cholesterol
to pregnenolone by the side chain cleavage enzyme, P450scc or
CYP11A1, is considered to be the rate-limiting step in steroidoge-
nesis and occurs in the mitochondria of steroid-synthesizing cells.
Pregnenolone is transported outside the mitochondria for sub-
sequent synthetic steps. The weak androgen, androstenedione is
produced via a delta4 pathway that ﬁrst involves the conversion
of pregnenolone to progesterone and then 17alpha hydroxyl prog-
esterone by the enzymes 3β hydroxysteroid dehydrogenase (3β
HSD) and 17alpha hydroxylase, respectively. Androstenedione is
formed from17alpha hydroxy-progesterone by 17,20 lyase activity.
In humans, the pathway for androgen synthesis largely involves the
delta5 pathway that produces dehydroepiandrosterone (DHEA) as
the precursor for androstenedione. Depending on the tissue exam-
ined, androstenedione can be converted to testosterone by Type 3
17β hydroxysteroid dehydrogenase (17βHSD) or to estrone by the
aromatase enzyme. Type 1 17βHSD is responsible for the conver-
sion of estrone to estradiol whereas aromatase can also synthesize
estradiol, using testosterone as the precursor (see Figure 1A; Rosen
and Cedars, 2007).
Inbrain andother steroid sensitive tissues, there are overlapping
functions that have been attributed to androgens and estrogens
based on studies showing that the brain is a rich source of aro-
matase activity and testosterone is a precursor to estradiol in brain
(Abdelgadire et al., 1994; Naftolin, 1994). Testosterone can also be
converted to the more potent androgen, DHT, by the 5α reduc-
tase enzyme (5αR; Krieger et al., 1983; Melcangi et al., 1985). For
many years, DHT was considered a prototypic androgen receptor
(AR) agonist, with greater binding activity at the AR compared
to testosterone (Zhou et al., 1995). Moreover, unlike testosterone,
DHT cannot be aromatized to estradiol-like metabolites. In con-
trast, recent data indicate that DHTmay be converted to products
with estrogen-like activity, but by enzymes other than aromatase
(Weihua et al., 2001, 2002).
The principal metabolites of DHT are 5α-androstane 3β, 17β
Diol (3β-Diol), and 5α- androstane 3α, 17β Diol (3α-Diol). Both
steroids have little activity at theAR,however 3β-Diol has amoder-
ate ability to bind and activate ERbeta (Kuiper et al., 1997;Weihua
et al., 2001). 3β-Diol is synthesized from DHT by the actions
of multiple enzymes including 3αHSD, 17αHSD, and 3βHSD,
whereas 3β Diol is metabolized to 6α- and 7α-triol by the actions
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FIGURE 1 | Biosynthetic pathway for gonadal steroid hormones. (A)
Shows known enzymes and intermediates leading to the synthesis of
estrogens and androgens from cholesterol. (B) Shows the metabolic steps
of dihydrotestosterone processing putatively involved in pre-receptor
regulation of ERbeta activation. 3α-Diol=5α androstane 3α, 17β Diol; 3β
Diol=5α androstane 3β, 17β Diol, RL-HSD=11-cis-retinol dehydrogenase
like 3α-HSD.
of CYP7b1 (Figure 1B; Jin and Penning, 2001; Gangloff et al.,
2003; Steckelbroeck et al., 2004; Penning et al., 2007). In contrast,
3α-Diol is synthesized from DHT through the actions of 3αHSD.
This reaction is a reversible reaction through the actions of “RoDH
Like” 3αHSD (RL–HSD; Bauman et al., 2006). Thus, any of these
enzymesmay be important in pre-receptor regulation of androgen
action. Based on the metabolism of DHT to 3β-Diol,Weihua et al.
(2001, 2002) suggested a role for ERbeta in mediating its actions
in prostate gland. Given the important role that estrogens play in
regulating the HPA axis, particularly those that bind ERbeta, these
DHTmetabolites could play an important role in the regulation of
non-reproductive functions such as stress reactivity in the rodent.
3β-DIOL AND THE REGULATION OF THE HPA AXIS
The ability of 3β-Diol to regulate the reactivity of the HPA axis
was ﬁrst described by Lund et al. (2004a) who tested the ability of
peripherally administered 3β-Diol-diproprionate to alter stress-
responsive CORT and ACTH secretion in castrated adult male
mice. These studies revealed that 3β-Diol treatmentwas as effective
as DHT in reducing the gain of stress-induced CORT and ACTH
secretion. Moreover, the effects of 3β-Diol could be blocked by
co-administration of the non-selective ER antagonist, tamoxifen,
but not by the AR antagonist, ﬂutamide, thus implicating estrogen
receptors in the actions of both DHT and 3β-Diol. Furthermore,
ERbeta agonists inhibited HPA reactivity in a fashion similar to
DHT and 3β-Diol, whereas ERalpha agonists did not.
Evidence for the PVN being the primary neural target of 3β-
Diol’s HPA inhibiting activity has also been demonstrated (Lund
et al., 2006). Using small pellets of beeswax as a carrier for hor-
mone, it was found that the stereotaxic application of 3β-Diol
to the PVN of castrated male rats mimicked the actions of both
central and peripherally administered DHT. Such local applica-
tion of the ERbeta agonist, diarylpropionitrile (DPN), could also
mimic the actions of DHT. The inhibitory actions of 3β-Diol and
DPNwere blocked by co-administration of tamoxifen,whereas the
AR antagonist, ﬂutamide had little effect. Although it is currently
unknownwhether 3β-Diol is produced by cells in or near the PVN,
the fact that mRNAs for the steroid metabolizing enzymes such as
5αR, 3αHSD, 17αHSD, and CYP7b1 are found in the PVN sug-
gests that local synthesis of the hormonemay be responsible (Lund
et al., 2006). Thus, the paracrine effects of 3β-Diol on nearby cells
of the PVN likely impact the function of HPA reactivity to stressors
through binding to ERbeta.
3β-Diol has also been shown to impact other neurobiologi-
cal systems through ERbeta. For example, Osborne et al. (2009)
demonstrated that 3β-Diol improved performance in the Mor-
ris water maze and Pendergast et al. (2008) demonstrated that
3β-Diol can regulate tyrosine hydroxylase expression in the locus
coeruleus.
In contrast to the actions of 3β-Diol-bound ERbeta, estradiol
appears to act primarily through ERalpha to augment HPA reac-
tivity. Estradiol and the ERalpha selective agonist, propylpyrazole-
triol (PPT), oppose the action of ERbeta agonists and consistently
increaseHPA reactivity to restraint stress (Lund et al., 2006). Given
the co-localization of ERalpha in GABAergic neurons in the peri-
PVN area, it has been hypothesized that ERalpha increases the gain
of the HPA axis through modulation of local inhibitory circuits
(Weiser and Handa, 2009).
Unknown at present are the mechanisms by which the HPA
axis distinguishes enhancing from inhibiting actions of estradiol,
a hormone that binds with similar high afﬁnity to both ERalpha
andERbeta (Kuiper et al., 1997; Lund et al., 2005). It is possible that
the ratio of ERalpha to ERbeta or the phenotype of neuron that
expresses ERalpha andERbetamaybe alteredunder different phys-
iological conditions. A greater alpha/beta ratio could cause a shift
toward enhanced gain and the opposite would be true under con-
ditions where ERbeta was elevated compared to ERalpha. Indeed,
it has been demonstrated that levels of ERbeta change in response
both to circulating glucocorticoid and estradiol levels (Isgor et al.,
2003; Suzuki and Handa, 2004). This would allow the gain of
the system to shift based on a given physiological state. An alter-
nate hypothesis is that estradiolworks predominantly by activating
ERalpha, whereas other endogenous ligands, such as 3β-Diol are
used to activate ERbeta.
MOLECULAR MECHANISM OF REGULATING CRH, AVP, AND
OT EXPRESSION
The receptors for estradiol (ERalpha and ERbeta) and for DHT
(androgen receptor) belong to the nuclear receptor (NR) super-
family of proteins. The NR superfamily is a large group of
transcription factors, most of which are ligand-activated. Char-
acteristics of the steroid receptor branch of the family include
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their ability to interact with three types of response elements:
(1) an inverted palindrome, (2) a composite element (Diamond
et al., 1990), and (3) a“tethering” element (Lefstin andYamamoto,
1998). Inverted palindromes are “classic” elements; they were the
ﬁrst described and for years were thought to be the sole means
by which a receptor could interact with DNA to regulate tran-
scription. Composite elements for steroid receptors consist of a
hormone response element half-site, and a half-site for amonomer
of another transcription factor. In fact, an example of this is the
negative glucocorticoid response element in the proximal region
of the CRH promoter (Malkoski et al., 1997; Malkoski and Dorin,
1999). The third type is a tethering or DNA-binding independent
element, one in which a transcription factor regulates the activity
of another transcription factor bound to its own DNA-binding
site. This mechanism is also called an alternate pathway. A well-
studied example is ER action mediated through an AP-1 or Sp-1
transcription factor bound to its DNA element (Kushner et al.,
2000; Safe and Kim, 2008). Awareness of these three modes of
regulation is critical for understanding ER regulation of CRH,VP,
and OT.
3β-DIOL-REGULATED CRH EXPRESSION
E2 regulated CRH expression was ﬁrst described byVamvakopou-
los and Chrousos (1993) who analyzed ER binding at estrogen
response element (ERE) half-sites. At the time alternate pathways
of gene regulation by ERs were only beginning to be explored and
ERbeta had yet to be discovered. Thus, given that the CRH pro-
moter is devoid of palindromic EREs, the ERE half-sites were a
logical target for analysis.
By 2004, the ability of ER regulation of gene expression via
alternate pathways was well established, particularly for SP-1 and
AP-1 (Kushner et al., 2000; Safe and Kim, 2008). The cAMP reg-
ulatory element binding protein (CREB) binding protein (CBP)
had been found to be a co-activator for AP-1, as well as CREB
(Bannister et al., 1995) and steroid receptor co-activators (SRCs)
were known to interact with CBP (reviewed in McKenna et al.,
1999). Based on these and numerous other data, Kushner et al.
(2000) proposed that ER regulation through AP-1 involved for-
mation of an ER:SRC:CBP complex. The fact that CRH activation
is critically dependent on the proximal cAMP regulatory element
(CRE; Seasholtz et al., 1988) suggested that its activation could
also be mediated via an alternate pathway, one that was regulated
via CREB.
The discovery of ERbeta (Kuiper et al., 1996) greatly broadened
the approach to CRH regulation. Using a widely used CRH pro-
moter:reporter construct (−663 to +124; Seasholtz et al., 1988;
Guardiola-Diaz et al., 1996), Miller et al. (2004) demonstrated
that various splice variants of ERbeta activated the CRH pro-
moter activity to different degrees. The most potent isoform was
ERbeta 1δ3,whichmediated a 12.5 fold increase in CRH promoter
activity in the presence of E2. In the presence of Tmx, ERbeta 1,
and ERbeta 2δ3 activated the promoter, as well. That an anti-
estrogen could activate the promoter corroborated the hypothesis
that CRH regulation involves an alternate pathway (Miller et al.,
2004). This hypothesis was strengthened by examining the occu-
pancy of the endogenous CRH promoter by ERalpha, ERbeta and
associated coregulators in a CRH expressing amygdalar cell line
(Kasckow et al., 1999; Lalmansingh and Uht, 2008). Results of
chromatin immuno-precipitation analysis followed by quantita-
tive PCR showed that ERalpha and beta occupancy in the region
of CRE at the proximal promoter increased by approximately 22-
and 12-fold respectively. The peak occupancy was different for the
two receptors. ERalpha and beta peaked at 1 and 3min, respec-
tively. Furthermore, the pattern of ERalpha and beta occupancy
correlated differentially with SRC-1 and CBP occupancy, suggest-
ing that ERalpha andbeta exist in distinct complexes (Lalmansingh
andUht, 2008). The increases in occupancy were tightly correlated
with the expression proﬁle of CRHmRNA, suggesting that the ER
interactions with the CRH promoter are functional.
More recently, another neuronal cell line that constitutively
expresses CRH was used to assess the effect of different estrogenic
ligands on CRH promoter activity (Ogura et al., 2008). E2 and
the ERbeta selective agonist diarylpropionitrile (DPN) increased
reporter activity in hypothalamic IVB cells whereas the ERalpha
agonist, propylpyrazole-triol (PPT) did not. These data suggest
that in certain cellular contexts ERbeta, but not ERalpha, activates
the CRH promoter. These data are germane to HPA axis regula-
tion by 3β-Diol, which has been shown to act via ERbeta at the VP
promoter (Pak et al., 2007).
Direct evidence for the regulation of CRH by 3β-Diol has been
reported byHuang et al. (2008). Using CHO-K1 cells, they showed
that E2 and 3β-Diol increased CRH promoter activity to the same
extent, and did so through both ERalpha and ERbeta. In distinc-
tion Tmx reduced the E2 and 3β-Diol induced promoter activity
to the level of vehicle in all cases, a ﬁnding consistent with an
ER-mediated response. More recently, we have found that 3β-Diol
treatment stimulates CRH expression rapidly; it increases mRNA
levels between 1 and 5mins of exposure (Stacey and Uht, unpub-
lished data). Thus, emerging evidence demonstrates that 3β-Diol
increases CRH expression and likely does so through an alternate
pathway of gene regulation.
3β-DIOL-REGULATED AVP EXPRESSION
Prior to investigating the effects of 3β-Diol in AVP regulation,
investigators had evaluated the role of ERalpha and ERbeta in
regulating AVP expression. Using reporter assays, the differential
regulation of AVPpromoter activity by ERalpha and betawas stud-
ied (Shapiro et al., 2000). These investigators traced ERalpha and
beta activity, in the presence of E2, to an upstream ERE, between
−5.5 and −4.0 kb and ERbeta repression to a proximal region of
the promoter that contains several AP-1 sites.
The effects of 3β-Diol at the AVP promoter, mediated through
ERbeta1 and its splice variant, ERbeta2, has also been exam-
ined (Pak et al., 2007). In a fashion similar to that shown by
Shapiro et al. (2000), ERbeta1 displayed constitutive activity in
the proximal promoter. Maximal constitutive activity required the
region between −740 b and 1.3 kb of the AVP promoter. ERbeta2
also displayed constitutive activity but approximately half of that
exhibited by ERbeta1 (Pak et al., 2007). In distinction to the studies
by Shapiro and colleagues, Pak et al. (2007) did not report that E2
down-regulated the constitutive activity of ERbeta1. Rather, in the
presence of ERbeta1, E2 had no effect whereas DHT and 3β-Diol
increased activity. In the presence of ERbeta2, however, E2 and 3β-
Diol increased activity whereas DHT had no effect. That 3β-Diol
increases AVP reporter activity through both ER-beta1 and -beta2
is striking, given that the difference between the two receptors has
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been traced to the ligand-binding domain. Lastly, Pak et al. (2007)
showed that expression of a GRIP/SRC-2-NR box abrogated the
3β-Diol effect through ERbeta1, suggesting that 3β-Diol elicits an
AF-2 conformation similar to E2. As the authors suggest, it will
be interesting to determine whether the spectrum of co-activators
required by 3β-Diol-bound ERbeta1 and ERbeta2 differ. Regard-
less of which co-activators are used, 3β-Diol clearly regulates AVP
expression.Moreover, sufﬁcient information is present in the liter-
ature to suggest that 3β-Diol could target AVP expressing neurons
in the PVN.
3β-DIOL-REGULATED OT EXPRESSION
For years, the OT promoter has been known to be estrogen
responsive (Richard and Zingg, 1990). However, dissection of
the molecular mechanisms of OT regulation has been hampered
by species differences in the upstream promoter and a complex
composite hormone response element within the proximal pro-
moter. A point in common across species is the location of the
primary site of estrogen regulation at about −160 bp (Richard
and Zingg, 1990; Adan et al., 1993). The composite response
element contains sequences in common with a consensus ERE;
however, the degree to which it binds ERalpha and/or beta is
species dependent.
Common to all species is the ability of two “orphan” receptors
to bind the response element. These are steroidogenic factor-1
(SF-1) and a chicken ovalbumin upstream promoter transcription
factor COUP–TF (Wehrenberg et al., 1994). The site is also bound
by other NRs such as the retinoic acid and thyroid hormone recep-
tors and the orphan receptor ERRα; however, the extent to which
they do so is again species dependent (Richard and Zingg, 1991;
Adan and Burbach, 1992; Lipkin et al., 1992; Burbach et al., 1994;
Lopes da Silva and Burbach, 1995; Chu andZingg, 1999;Dellovade
et al., 1999; Stedronsky et al., 2002; Koohi et al., 2005; Wang et al.,
2006).
Although the OT ERE has been studied for its ability to inter-
act with a number of different receptors, differences in regulation
elicited by various ligands has not been well-studied. Koohi et al.
(2005) compared E2 to Tamoxifen, raloxifene, and ICI 180,780
effects at the bovine OT promoter in the presence of ERalpha.
They found that the proﬁle of all of the “antagonists”was in keep-
ing with their activity through alternate pathways. That is, when
used alone they elicited activity at the OT response element but
not at an individual vitellogenin ERE, a site which is very close
to being a consensus sequence. With respect to 3β-Diol effects
on OT expression, we have recently found that ERalpha and beta
are differentially recruited to the OT promoter. Furthermore, this
recruitment is a function of receptor ligand (Figure 2). A hypo-
thalamic cell line derived from mice (mHypoE-38; Mayer et al.,
2009) was used for ChIP analysis. By 30min, 3β-Diol stimulated
ERbeta occupancy to fourfold that of vehicle. At 60min, both
ligands reduced promoter occupancy by both receptors (Figure 2;
unpublisheddata). Thus,3β-Diol andE2differentially regulateOT
promoter occupancy by ERalpha and ERbeta in a time dependent
manner.
Taken together, the available molecular data underscore the
complexity of OT regulation. An important point to be taken is
that the species differences are so striking that generalizations with
FIGURE 2 | E2 and 3β-Diol lead to different patterns of promoter
occupancy by ERα and ERβ. mHypoE-38 cells were treated with E2
(10−7 M) or 3β-Diol (10−7 M) for 30 or 60min. Anti-ERα or anti-ERβ antiserum
was used for chromatin immuno-precipitation followed by quantitative PCR
of the OT promoter. n=4; Bars represent the mean±SEM and are
presented as the fold difference of vehicle. **, p <0.01, ***, p <0.001.
respect to regulation of this stress regulatory neuropeptide can
only be made with caution.
SIGNIFICANCE
Clinical and preclinical studies of MDD provide evidence linking
the reported dysregulation of the HPA axis and depressive neu-
ropathology. This dysregulation is characterized by increased cor-
tisol secretory responses, enlarged adrenal gland volume (Rubin
et al., 1987, 1996) and elevated CRH in cerebrospinal ﬂuid
(Nemeroff et al., 1984) in depressed patients. Furthermore,
20–40% of depressed patients are dexamethasone (DEX) non-
suppressors (i.e., DEX suppresses ACTH and cortisol to a much
smaller extent than healthy controls) and the inability of DEX to
suppress cortisol release following a CRH stimulation can distin-
guish greater than 90% of depressed patients from non-depressed
controls (Heuser et al., 1994). Neurobiological evidence for HPA
involvement in MDD comes from postmortem studies showing
that the PVN of depressed patients contains four times the num-
ber of CRH expressing cells (Raadsheer et al., 1993). Increases
in the number of oxytocin and AVP-ir neurons in the PVN have
been reported as well (Raadsheer et al., 1994; Purba et al., 1996).
Of interest, plasma vasopressin levels have been shown to be
elevated in MDD patients (Van Londen et al., 1997). Similarly,
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nocturnal plasma OT levels have recently been reported to be ele-
vated in individuals with major depression (Parker et al., 2010),
although earlier studies show a negative correlation between oxy-
tocin levels and depressive symptoms (Scantamburlo et al., 2007).
Pulsatile patterns of oxytocin release have also been reported
to be more variable in depressed women (Cyranowski et al.,
2008). Consequently, estrogen and androgen signaling in brain
may inﬂuence the regulation of HPA axis function and may
impact the dysregulation of the HPA axis seen in patients with
affective disorders thus underlying susceptibility to affective dis-
orders. Further work is required to identify estrogen receptor
regulated genes that may be targets for future pharmacological
intervention.
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